{
    "root": "03a7ffa9-1fe3-4844-8095-4d2945484441",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metoprolol succinate",
    "value": "20250219",
    "ingredients": [
        {
            "name": "METOPROLOL SUCCINATE",
            "code": "TH25PD4CCB"
        },
        {
            "name": "ACETYLTRIBUTYL CITRATE",
            "code": "0ZBX0N59RZ"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "Hydroxypropyl Cellulose, Unspecified",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYDROGENATED COTTONSEED OIL",
            "code": "Z82Y2C65EA"
        },
        {
            "name": "METHYLENE CHLORIDE",
            "code": "588X2YUY0A"
        },
        {
            "name": "ETHYLCELLULOSE (10 MPA.S)",
            "code": "3DYK7UYZ62"
        }
    ],
    "indications": "metoprolol succinate extended-release tablets beta-adrenergic blocker indicated treatment : hypertension , lower blood pressure . lowering blood pressure reduces risk fatal non-fatal cardiovascular events , primarily strokes myocardial infarctions . ( 1.1 ) angina pectoris . ( 1.2 ) heart failure , reduce risk cardiovascular mortality heart failure hospitalizations patients heart failure . ( 1.3 )",
    "contraindications": "administer daily . titrate weekly longer intervals needed tolerated . ( 2 ) hypertension : starting dose 25 100 mg. ( 2.1 ) angina pectoris : starting dose 100 mg. ( 2.2 ) heart failure : starting dose 12.5 25 mg. ( 2.3 ) switching immediate-release metoprolol metoprolol succinate extended-release tablets : total daily dose metoprolol succinate extended-release tablets . ( 2 )",
    "warningsAndPrecautions": "metoprolol succinate extended-release tablets usp , 25 mg white off-white , oval shaped , film-coated tablets , debossed \u201c \u201d \u201c 1 \u201d separated breakline one side breakline side . supplied following blistercards unit dose boxes : blistercards 30 ndc 0615-7823-39 blistercards 28 ndc 0615-7823-28 blistercards 15 ndc 0615-7823-05 unit dose boxes 30 ndc 0615-7823-30 metoprolol succinate extended-release tablets usp , 50 mg white off-white , round shaped , film-coated tablets , debossed \u201c \u201d \u201c 2 \u201d separated breakline one side plain side . supplied following blistercards : blistercards 30 ndc 0615-7824-39 blistercards 28 ndc 0615-7824-28 blistercards 15 ndc 0615-7824-05 store 20\u00b0-25\u00b0c ( 68\u00b0-77\u00b0f ) ; [ usp controlled room temperature . ]",
    "adverseReactions": "metoprolol succinate extended-release tablets contraindicated severe bradycardia , second- third-degree heart block , cardiogenic shock , decompensated heart failure , sick sinus syndrome ( unless permanent pacemaker place ) , patients hypersensitive component product .",
    "indications_original": "Metoprolol succinate extended-release tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure.\u00a0( 1.3)",
    "contraindications_original": "Administer once daily. Titrate at weekly or longer intervals as needed and tolerated. ( 2 ) Hypertension: Starting dose is 25 to 100 mg. ( 2.1 ) Angina Pectoris: Starting dose is 100 mg. ( 2.2 ) Heart Failure: Starting dose is 12.5 or 25 mg. ( 2.3 ) Switching from immediate-release metoprolol to metoprolol succinate extended-release tablets: use the same total daily dose of metoprolol succinate extended-release tablets. ( 2)",
    "warningsAndPrecautions_original": "Metoprolol succinate extended-release tablets USP, 25 mg are white to off-white, oval shaped, film-coated tablets, debossed with \u201cM\u201d and \u201c1\u201d separated by breakline on one side and breakline on other side. They are supplied in the following blistercards and unit dose boxes:\n                  Blistercards of 30\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 0615-7823-39\n                  Blistercards of 28\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 0615-7823-28\n                  Blistercards of 15\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 0615-7823-05\n                  Unit dose boxes of 30\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 0615-7823-30\n                  Metoprolol succinate extended-release tablets USP, 50 mg are white to off-white, round shaped, film-coated tablets, debossed with\u00a0 \u201cM\u201d and \u201c2\u201d separated by breakline on one side and plain on other side. They are supplied in the following blistercards:\n                  Blistercards of 30\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 0615-7824-39\n                  Blistercards of 28\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 0615-7824-28\n                  Blistercards of 15\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 0615-7824-05\n                  Store at 20\u00b0-25\u00b0C (68\u00b0-77\u00b0F); [See USP Controlled Room Temperature.]",
    "adverseReactions_original": "Metoprolol succinate extended-release tablets are contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product."
}